A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

NCT06008288 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS P.G12C
Pancreatic Cancer
Solid Tumor

Interventions

DRUG: JAB-21822

Sponsor

Allist Pharmaceuticals, Inc.